Background: The long-term (>12 months) prevalence, predictors, and trajectory of post-stroke cognitive deficits are not well established, especially at a community level. This study investigated the longitudinal course and prevalence of cognitive impairment in an incidence cohort, identifying factors associated with declining cognition. Methods: Two hundred fifty-seven participants (mean age = 67.93 ± 13.59) of first-ever stroke survivors, completed cognitive assessments within 2 weeks post stroke, and/or 1, 6, 12, and 48-month. Multivariate linear and logistic models were used to identify baseline predictors (reported as OR with 95% CI) and trajectory of cognitive impairment. Results: Cognitive functioning significantly declined by 2.8 points by 4 years post stroke. Eighty-four percent of stroke survivors had cognitive impairment indicative of post-stroke dementia (mean Montreal cognitive assessment = 20 ± 4.7) at 4-year. There were significant as-sociations between progressive cognitive decline and the -following factors: male gender (OR 2.9, 95% CI 1.6–5.9, -p = 0.0171), coronary artery disease (OR 2.96, 95% CI 1.35–6.49, p = 0.0070), arrhythmia (OR 2.21, 95% CI 1.07–4.57, p = 0.0317), not in a relationship (OR 2.8, 95% CI 1.4–5.50, p < 0.0001), and not employed (OR 4.9, 95% CI 1.9–12.1, p < 0.0001). Conclusions: Cognitive deficits remain highly prevalent at 4-year post stroke. Early identification of those at higher risk of declining cognition is vital to target rehabilitation interventions at the acute stage and improve overall outcomes.

Keywords:
Stroke, Neuropsychology, Cognitive Impairment, Long term, Prevalence, Trajectory, Determinants
1.
Melkas S, Jokinen H, Hietanen M, Erkinjuntti T: Poststroke cognitive impairment and dementia: prevalence, diagnosis, and treatment. Degener Neurol Neuromuscul Dis 2014; 4: 21–27.
2.
Jokinen H, Melkas S, Ylikoski R, Pohjasvaara T, Kaste M, Erkinjuntti T, et al: Post-stroke cognitive impairment is common even after successful clinical recovery. Eur J Neurol 2015; 22: 1288–1294.
3.
Pendlebury ST, Rothwell PM: Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol 2009; 8: 1006–1018.
4.
Kalaria RN, Akinyemi R, Ihara M: Stroke injury, cognitive impairment and vascular dementia. Biochim Biophys Acta 2016; 1862: 915–925.
5.
Pendlebury ST, Chen PJ, Bull L, Silver L, Mehta Z, Rothwell PM: Methodological factors in determining rates of dementia in transient ischemic attack and stroke: (I) impact of baseline selection bias. Stroke 2015; 46: 641–646.
6.
Pendlebury ST, Chen PJ, Welch SJ, Cuthbertson FC, Wharton RM, Mehta Z, et al: Methodological factors in determining risk of dementia after transient ischemic attack and stroke: (II) effect of attrition on follow-up. Stroke 2015; 46: 1494–1500.
7.
del Ser T, Barba R, Morin MM, Domingo J, Cemillan C, Pondal M, et al: Evolution of cognitive impairment after stroke and risk factors for delayed progression. Stroke 2005; 36: 2670–2675.
8.
Levine DA, Galecki AT, Langa KM, Unverzagt FW, Kabeto MU, Giordani B, et al: Trajectory of cognitive decline after incident stroke. JAMA 2015; 314: 41–51.
9.
Krishnamurthi R, Jones A, Barber PA, Barker-Collo S, McPherson K, Bennett D, et al: Methodology of a population-based stroke and TIA incidence and outcomes study: the Auckland Regional Community Stroke Study (ARCOS IV) 2011–2012. Int J Stroke 2014; 9: 140–147.
10.
Aho K, Harmsen P, Hatano S, Marquardsen J, Smirnov VE, Strasser T: Cerebrovascular disease in the community: results of a WHO collaborative study. Bull World Health Organ 1980; 58: 113–130.
11.
Dong Y, Sharma VK, Chan BP, Venketasubramanian N, Teoh HL, Seet RC, et al: The montreal cognitive assessment (MoCA) is superior to the mini-mental state examination (MMSE) for the detection of vascular cognitive impairment after acute stroke. J Neurol Sci 2010; 299: 15–18.
12.
Nasreddine Z, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al: The montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005; 53: 695–699.
13.
Burton L, Tyson SF: Screening for cognitive impairment after stroke: a systematic review of psychometric properties and clinical utility. J Rehabil Med 2015; 47: 193–203.
14.
Chan E, Altendorff S, Healy C, Werring DJ, Cipolotti L: The test accuracy of the Montreal Cognitive Assessment (MoCA) by stroke lateralisation. J Neurol Sci 2017; 373: 100–104.
15.
Pendlebury ST, Mariz J, Bull L, Mehta Z, Rothwell PM: MoCA, ACE-R, and MMSE versus the national institute of neurological disorders and stroke-Canadian stroke network vascular cognitive impairment harmonization standards neuropsychological battery after TIA and stroke. Stroke 2012; 43: 464–469.
16.
Mai LM, Sposato LA, Rothwell PM, Hachiniski V, Pendlebury ST: A comparison between the MoCA and the MMSE visuoexecutive sub-tests in detecting abnormalities in TIA/stroke patients. Int J Stroke 2016; 11: 420–424.
17.
Douiri A, Rudd AG, Wolfe CD: Prevalence of poststroke cognitive impairment: South London Stroke Register 1995–2010. Stroke 2013; 44: 138–145.
18.
Chen X, Duan L, Han Y, Tian L, Dai Q, Wang S, et al: Predictors for vascular cognitive impairment in stroke patients. BMC Neurol 2016; 16: 115.
19.
Singh-Manoux A, Fayosse A, Sabia S, Canonico M, Bobak M, Elbaz A, et al: Atrial fibrillation as a risk factor for cognitive decline and dementia. Eur Heart J 2017; 38: 2612–2618.
20.
de Bruijn RF, Ikram MA: Cardiovascular risk factors and future risk of Alzheimer’s disease. BMC Med 2014; 12: 130.
21.
Renjen PN, Gauba C, Chaudhari D: Cognitive Impairment after stroke. Cureus 2015; 7:e335.
22.
Muela HC, Costa-Hong VA, Yassuda MS, Moraes NC, Memória CM, Machado MF, et al: Hypertension severity is associated with impaired cognitive performance. J Am Heart Assoc 2017; 6:pii:e004579.
23.
Kozyolkin A, Kuznietsov A, Novikova L: Characteristics and dynamics of cognitive impairment in patients with primary and recurrent cerebral ischemic hemispheric stroke. Zaporozhye Med J 2014; 4: 56–59.
24.
Ellwardt L, Aartsen M, Deeg D, Steverink N: Does loneliness mediate the relation between social support and cognitive functioning in later life? Soc Sci Med 2013; 98: 116–124.
25.
Mirza S, Portegies ML, Wolters FJ, Hofman A, Koudstaal PJ, Tiemeier H, et al: Higher education is associated with a lower risk of dementia after a stroke or TIA. The Rotterdam Study. Neuroepidemiology 2016; 46: 120–127.
26.
Marshall I, Wang Y, Crichton S, McKevitt C, Rudd AG, Wolfe CD: The effects of socioeconomic status on stroke risk and outcomes. Lancet Neurol 2015; 14: 1206–1218.
27.
Zweifel-Zehnder AE, Stienen MN, Chicherio C, Studerus-Germann A, Blasi S, Rossi S, et al: Call for uniform neuropsychological assessment after aneurysmal subarachnoid hemorrhage: swiss recommendations. Acta Neurochir (Wien) 2015; 157: 1449–1458.
28.
Stienen MN, Weisshaupt R, Fandino J, Fung C, Keller E, Hildebrandt G, et al: Current practice in neuropsychological outcome reporting after aneurysmal subarachnoid haemorrhage. Acta Neurochir (Wien) 2013; 155: 2045–2051.
29.
Chu A, Wong GK, Lam SW, Wong A, Ngai K, Poon WS, et al: Cognitive impairment in aneurysmal subarachnoid hemorrhage patients with delayed cerebral infarction: prevalence and pattern. Acta Neurochir Suppl 2015; 120: 303–306.
30.
Ellmore TM, Rohlffs F, Khursheed F: FMRI of working memory impairment after recovery from subarachnoid hemorrhage. Front Neurol 2013; 4: 179.
31.
Thompson JN, Sheldrick R, Berry E: Cognitive and mental health difficulties following subarachnoid haemorrhage. Neuropsychol Rehabil 2011; 21: 92–102.
32.
Kapapa T, Konig R: Subarachnoid hemorrhage: epidemiology , management and new approaches to measure outcome; in Gray L (ed): Subarachnoid Hemorrhage Epidemiology, Management and Long-Term Health Effects. New York, Nova Science Publishers, 2015, pp 59–98.
33.
le Roux AA, Wallace MC: Outcome and cost of aneurysmal subarachnoid hemorrhage. Neurosurg Clin N Am 2010; 21: 235–246.
34.
Horstmann S, Rizos T, Rauch G, Arden C, Veltkamp R: Feasibility of the montreal cognitive assessment in acute stroke patients. Eur J Neurol 2014; 21: 1387–1393.
35.
Levine DA, Galecki AT, Langa KM, Unverzagt FW, Kabeto MU, Giordani B, et al: Trajectory of cognitive decline after incident stroke. JAMA 2015; 314: 41–51.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.